FDA Approves IL-15 Receptor Agonist for BCG-Unresponsive NMIBC
Nogapendekin alfa inbakicept-pmln has been approved for use with BCG for the treatment of BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.